Enteral Delivery of Pravastatin Sodium Tablets: Effect of Compounding into a Liquid Form and Co-Administration of Enteral Nutrition.
| Autor: | Logrippo S; Hospital Pharmacy, Santa Maria della Stella Hospital, USL Umbria 2, 05018 Orvieto, Italy.; Hospital Pharmacy, Engles Profili Hospital, AST Ancona, 60044 Fabriano, Italy., Ganzetti R; Hospital Pharmacy, Carlo Urbani Hospital, AST Ancona, 60035 Jesi, Italy., Sestili M; Territorial Pharmaceutical Service, AST Ancona, 60035 Jesi, Italy., Perinelli DR; CHIP Building, School of Pharmacy, University of Camerino, 62032 Camerino, Italy., Cespi M; CHIP Building, School of Pharmacy, University of Camerino, 62032 Camerino, Italy., Bonacucina G; CHIP Building, School of Pharmacy, University of Camerino, 62032 Camerino, Italy. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Pharmacy (Basel, Switzerland) [Pharmacy (Basel)] 2024 Feb 09; Vol. 12 (1). Date of Electronic Publication: 2024 Feb 09. |
| DOI: | 10.3390/pharmacy12010032 |
| Abstrakt: | Background: Compounding solid oral dosage forms into liquid preparations is a common practice for administering drug therapy to patients with swallowing difficulties. This is particularly relevant for those on enteral nutrition, where factors such as the administration procedure and co-administration of enteral nutrition play crucial roles in effective drug delivery. Due to the limited studies focused on this practice, the impact of co-administered nutrition remains unclear. Methods: Pravastatin tablets were compounded into two liquid formulations and administered through three independent tubes for ten cycles. The drug amount was quantified upstream and downstream of the tubes both with and without different (fiber content) nutritional boluses. Results: The compounding procedure did not lower the drug amount with respect to the original tablets. However, when the liquid formulation was pumped through the tubes, a statistically significant reduction in the pravastatin administered (between 4.6% and 11.3%) was observed. The co-administration of different nutritional boluses or the compounding procedure did not affect the general results. Conclusions: Pravastatin loss appears unavoidable when administered via the enteral tube. Although, in this case, the loss was of limited clinical relevance, it is important not to underestimate this phenomenon, especially with drugs having a narrow therapeutic index. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|